Introduction: A major limitation in cancer treatment is the development of multidrug resistance (MDR). Tamoxifen is a substrate of multidrug resistance protein 1 (MDR1) or P-glycoprotein, while curcumin is known as MDR1 inhibitor. The objective of this study was to analyze cell viability and MDR1 mRNA expressions in breast cancer cells, treated with tamoxifen alone or in combination with curcumin. Method: MCF-7 breast cancer cells lines were treated with tamoxifen 1 M alone or in combination with curcumin at 10, 20 and 35 M, while tamoxifenverapamil (50 M) was used as positive control for MDR1 inhibitor. The cells were harvested and counted for their viability and extracted for total RNA. MDR1 mRNA expressions were quantified using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Results: MCF-7 cells viability were decreased in concomitant treatment of tamoxifen + curcumin compared with tamoxifen alone, and appeared to be dosedependent. The expressions of MDR1 mRNA were shown to be suppressed in MCF-7 cells co-treated with tamoxifen and curcumin. Conclusion: Concomitant administration of tamoxifen and curcumin resulted in an increased anticancer activity compared with tamoxifen alone. This effect is thought to be via the suppression of MDR1 mRNA expressions.
INTRODUCTION
Breast cancer is the most common type of cancer in women worldwide and also the second of the most common type of cancer overall. In 2012, approximately 1.7 million new breast cancers were diagnosed, which represents about 25% of all cancers in women. 1 Breast cancer is hormone related. For estrogen receptor positive type, up to date, tamoxifen is still used as first line pharmacological treatment. [2] [3] [4] Unfortunately, after about 10 months of treatment, 40 percent of patients are starting to relapse. 5 6 Many studies have been done to elucidate the mechanism of resistance of breast cancer cells to tamoxifen. 4 7 8 One of the cause of cancer cells resistance are the development of multidrug resistance (MDR). This phenomenon is marked with the increased expression of drug efflux transporters, such as multidrug resistance 1 (MDR1), breast cancer resistance protein (BCRP) and MRP. 4 9 10 MDR1 or often called as P-glycoprotein is a plasma membrane protein which belongs to ABC (ATP-binding cassette) * Author to whom correspondence should be addressed. superfamily of transporters. The substrates of this transporters will be transported out of the cells and will result in the decrease concentrations of drug in the cells. 11 12 Many cancer drugs were known to induce MDR1 expressions, including antracyclin (doxorubicin, epirubicin), vinca alcaloids (vincristine, vinblastine0 and tamoxifen. 11 13 MDR1 inhibitors has been used in many studies to overcome the overexpression of MDR1. A group of substances such as verapamil, cyclosporine A, phenothiazine, reserpine are shown to reduce overexpression of MDR1 and eventually increase drug concentrations. Unfortunately, those drugs are not specific. They required high concentrations to act as MDR1 inhibitors which resulted in a relatively high toxicity. 12 Curcumin is a phenolic compound derived from Curcuma longa. Curcumin has wide biological activities as as antioxidant, anti-inflammatory and anticancer. 14 15 Curcuma is also shown to be a potent MDR1 and BCRP inhibitors in human cervical carcinoma KB-V2 cells and gastric cancer cell line. 16 17 However, whether curcumin have an inhibitory activity in tamoxifeninduced breast cancer cells is still unknown. In this study, we aimed to analyze the role of curcumin in the prevention of breast cancer cells resistance development to tamoxifen through the inhibition of MDR1 expressions.
METHODS

Materials and Reagents
This is an in vitro study in MCF7 breast cancer cells. Breast cancer cell lines MCF-7 was a kind gift from Makmal Laboratory (FKUI, Indonesia). Tamoxifen 
Cell Culture
Cell were cultured on DMEM supplemented with fetal bovine serum (FBS) 10%, fungizone 2.5 g/mL, penicillin 100 IU/mL and streptomycin 100 ug/mL at 37 C and 5% CO 2 . Cells were sub-cultured at about 90% confluency and placed to a 6-well plates for further study.
Preparation of Drugs
Tamoxifen, verapamil and curcumin were dissolved in DMSO and then diluted with DMEM into desired concentrations. Final concentrations of DMSO were less than 0.001%.
Tamoxifen Dose Determination
We determine the optimum dose tamoxifen that can reduce the viability of MCF-7 cells, a 1 × 10 5 cells were placed on a 6-well plates and treated with tamoxifen at concentrations of 0.25 M, 1 M and 4 M. Medium were replaced every two days and tamoxifen were reapplied. Tamoxifen were dissolved in DMSO (less than 0.001%). Every two days, cells were trypsinized and counted using trypan blue exclusion method.
Drug Treatment
MCF-7 cells at 1 × 10 5 cells were cultured on a 6-well plate and incubated for 24 prior to drug treatment. Tamoxifen and curcumin (10, 20 and 35 M) were applied to the cells and were changed at day 1, 4, 6, 9, 12 days. DMSO was used as negative control and verapamil 50 M was used as positive control for MDR1 inhibitor. Cells were harvested using Triple Express and counted, then were subjected for total RNA extraction using a total RNA mini kit reagent (Geneaid) using procedure provided by the manufacturer. Samples were prepared by mixing 200 nM of each primer, 7.5 uL KAPA SYBR Fast qPCR master mix Green, 0.4 mL KAPA RT Mix (50×), 0.4 mL dUTP, 275 ng RNA template, and RNase-free water to 15 mL. Samples were then incubated in the qRT-PCR machine with the following conditions: 5 min at 42 C for cDNA synthesis, 5 min at 95 C for reverse transcriptase inactivation, and 35 cycles consisting of 3 seconds at 95 C for denaturation stage and 1 min at 64 C for annealing stage, 30 seconds for the extension phase. After that final elongation for 5 minutes and 30 seconds to the cycle 81 times for melting time. Threshold value (Ct) was calculated automatically by the software. The data is then processed according to the Livak method. 18 Gene target in this study were MDR1/P-glycoprotein, whereas the reference gene used was GAPDH.
RESULT
To determine optimum dose of tamoxifen that induced cancer cells resistance to drugs, we exposed MCF-7 cells to several concentrations of tamoxifen. We found that 1 M of tamoxifen was potent enough to suppress cell growth and after five days of culture resulted in an increase in cell growth (Fig. 1) .
We used tamoxifen 1 M for further experiment and applied them to MCF-7 with and without curcumin (10 M, 20 M and 35 M) or verapamil 50 M. We observed that addition of curcumin or verapamil (as positive control of MDR1 inhibitor) to tamoxifen might decreased cell viability as compared to tamoxifen alone, and the effect was shown to be dose dependent (Fig. 2) .
Our result showed that initially tamoxifen reduced the expression of MDR1 expressions (normalized to GAPDH as reference gene) compared to control (DMSO), but after five days of treatment, there was increased in expressions (Fig. 3) . Addition of curcumin 10, 20 and 35 M or verapamil 50 M were shown to decreased MDR1 expressions induced by continuous treatment of tamoxifen. The decreased in MDR1 mRNA expressions was shown to be dose-dependent. Curcumin at 20 and 35 M was able to decrease MDR1 expressions as potent as verapamil (as positive control of MDR1 inhibitor).
DISCUSSION
Our study was aimed to investigate the role of curcumin in inhibiting MDR1. We started our study by determining the most appropriate dose to induce drug resistance in MCF-7 cancer cells and we found that 1 M is the most appropriate dose. Our result is in accordance with the result by Tehrani 19 which showed that tamoxifen 1 M reduced about 40% of MCF7 cell viability. This result is also consistent with previous studies by Motahari 20 and Lykkesfeldt 21 in T47D breast cancer cells that confirmed that 1 M of tamoxifen is adequate to induce tamoxifen resistance. Therefore, we used tamoxifen 1 M for further experiments.
We showed that cell viability in MCF7 cancer cell induced by tamoxifen began to increase from Day 6. Whether this effect is reversible or not, is still undetermined. Study by Motahari 20 indicates that stabile resistance phenotype of tamoxifen can be achieved after three months of continuous culture. Curcumin was able to suppress the cell viability in tamoxifen-induced MCF-7 cells, and the effect was shown to be dose dependent.
In our study, tamoxifen was initially reduced MDR1 mRNA expression and began to increase on Day 6. Study by Teft 10 and Sane 22 proved that tamoxifen can induce MDR1 by activating pregnane X receptor (PXR), a transcription factor. Active form of PXR will form heterodimer with Retinoid X Receptor (RXR), then bind to PXR responsive elements that stimulates MDR1 gene. 22 Harmsen et al. 23 also showed the effect of tamoxifen binding to PXR in colon cancer of adenocarcinoma type. This binding resulted in the decreased of doxorubicin concentrations in cancer cells. 23 Our result showed that curcumin in combination reduced cell viability along with decreased MDR1 expression. This phenomenon was also showed in other types of cancer. Study by Tang 24 showed that curcumin reduced MDR1 expressions in human gastric carcinoma cell line along with increased vincristine concentration. Mechanism on how curcumin inhibits MDR1 were shown by Labbozzetta 25 and Anuchapreeda. 16 Results by Labbozzetta 25 revealed that curcumin inhibits MDR1 in tumor cells by occupying MDR1 substrate binding site. While study by Anuchapreeda 16 showed that curcumin inhibits MDR1 by inhibiting ATP hydrolysis by MDR1-ATPase so that there were no energy for efflux.
CONCLUSION
We conclude that concomitant administration of tamoxifen and curcumin resulted in an increased anticancer activity compared with tamoxifen alone. The magnitude of viability reduction was proportional to dose and the time of exposure. This effect is thought to be via the suppression of MDR1 mRNA expressions.
